Pharmaceutical News

RSS

Merck's NEXPLANON 68 mg now available in the U.S.

Merck today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

10 Nov 2011

Study: Omega-3 supplements can decrease inflammation, anxiety

A recent study gauging the impact of consuming more fish oil showed a marked reduction both in inflammation and, surprisingly, in anxiety among a cohort of healthy young people.

10 Nov 2011

PCMD researcher receives Alzheimer's Association grant to study dementia

The US-based Alzheimer's Association has awarded Dr. David Llewellyn of Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, a prestigious two-year $100,000 New Investigator Research Grant to further his dementia research.

10 Nov 2011

Patients with Parkinson's may have increased risk of leg motor restlessness

People with Parkinson's disease may be more likely to have a movement disorder called leg motor restlessness, but not true restless legs syndrome as previous studies have suggested, according to a study published in the November 9, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

10 Nov 2011

New epigenetic therapy may treat recurrent metastatic NSCLC

Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential in this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

10 Nov 2011

Another tool to fight pharmacy crime through Twitter

...

9 Nov 2011

Study reveals need for defining optimal amount of iron in infant formula

A 10-year follow-up study examining iron-fortified vs. low-iron infant formula suggests that infants with high hemoglobin levels who received iron fortified infant formula have poorer long-term developmental outcomes.

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

Viagra may improve antitumor immunity in people with melanoma

At first it sounds like good news: The body's own immune system gets active in almost every cancer - however, not necessarily for the benefit of the patient. "We distinguish between two different types of immune response," says Professor Dr. Viktor Umansky, immunologist at DKFZ and University Medical Center Mannheim. "On the one hand, cells of the immune system specifically attack tumor cells.

9 Nov 2011

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the companies.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

QRxPharma receives FDA written acceptance for review of MoxDuo IR NDA

QRxPharma Limited announced today it received written acceptance from the United States Food and Drug Administration (FDA) for review of the MoxDuo IR New Drug Application (NDA) filed earlier this year.

9 Nov 2011

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.

9 Nov 2011

BioSpecifics reports $0.3M net income for third quarter 2011 vs. $0.5M net loss for third quarter 2010

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe today announced its financial results for the third quarter ended September 30, 2011 and provided a corporate update. For the quarter, the Company reported net income of $0.3 million or $0.04 per share on a basic and on a fully diluted basis.

9 Nov 2011

Lapatinib drug could also treat head and neck cancers

A class of drugs used to treat breast cancers which overproduce a protein called HER2 could also treat other types of cancer - particularly head and neck cancers, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool this week.

8 Nov 2011

FDA grants Fast Track designation to Opexa's Tovaxin for treatment of SPMS

Opexa Therapeutics, Inc., announced today that its lead drug candidate Tovaxin® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Secondary Progressive Multiple Sclerosis.

8 Nov 2011

UM launches campaign on medication adherence in Baltimore

Months before U.S. Surgeon General Regina Benjamin, MD, MBA, came to Baltimore on Nov. 2 to officially launch the city's leg of a three-year national campaign to raise awareness about medication adherence, pharmacy students had already taken up the challenge, said Cherokee Layson-Wolf, PharmD, CGP, associate professor of pharmacy practice and science at the University of Maryland School of Pharmacy.

8 Nov 2011

QRxPharma receives date for US pain drug launch, pending approval

Australian pain-relief drug developer QRxPharma (QRX) has announced today that they have received from the US Food & Drug Adminstration.

8 Nov 2011

Congress examines options to improve availability of prescription drugs

Shortages of prescription drugs are leaving a growing number of patients waiting for life-saving medicines. Federal officials say the number of prescriptions in short supply tripled from 2005 to 2010. Limited supplies of some drugs have sent prices soaring 1,000 times above normal.

8 Nov 2011

Children's Hospital project to investigate effectiveness of BET antagonists against HIV

Terri Finkel, M.D., Ph.D., chief of Rheumatology at Children's Hospital and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, will pursue an innovative global health research project, titled "Use of a BET Antagonist to Control and Cure HIV Infection."

8 Nov 2011